ES2061496T3 - INTRALESIONAL TREATMENT OF BASAL CELL CARCINOMA WITH RECOMBINANT ALPHA-HUMAN INTERFERON. - Google Patents

INTRALESIONAL TREATMENT OF BASAL CELL CARCINOMA WITH RECOMBINANT ALPHA-HUMAN INTERFERON.

Info

Publication number
ES2061496T3
ES2061496T3 ES87304642T ES87304642T ES2061496T3 ES 2061496 T3 ES2061496 T3 ES 2061496T3 ES 87304642 T ES87304642 T ES 87304642T ES 87304642 T ES87304642 T ES 87304642T ES 2061496 T3 ES2061496 T3 ES 2061496T3
Authority
ES
Spain
Prior art keywords
cell carcinoma
basal cell
human interferon
recombinant alpha
intralesional treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87304642T
Other languages
Spanish (es)
Inventor
Daniel Jay Tanner
Edwin Arnold Peets
Kenneth Albert Smiles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2061496T3 publication Critical patent/ES2061496T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL CARCINOMA DE CELULAS BASALES HUMANAS SE TRATA CON EXITO MEDIANTE ADMINISTRACION INTRALESIONAL DE INTERFERON ALFA HUMANO RECOMBINANTE, ESPECIALMENTE INTERFERON ALFA-2B. SE DESCRIBE LA PREPARACION DE COMPOSICIONES FARMACEUTICAS ADECUADAS.HUMAN BASAL CELL CARCINOMA IS TREATED SUCCESSFULLY BY INTRALESIONAL ADMINISTRATION OF INTERFERON RECOMBINANT HUMAN ALPHA, ESPECIALLY INTERFERED ALPHA-2B. THE PREPARATION OF APPROPRIATE PHARMACEUTICAL COMPOSITIONS IS DESCRIBED.

ES87304642T 1986-05-27 1987-05-26 INTRALESIONAL TREATMENT OF BASAL CELL CARCINOMA WITH RECOMBINANT ALPHA-HUMAN INTERFERON. Expired - Lifetime ES2061496T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86664486A 1986-05-27 1986-05-27

Publications (1)

Publication Number Publication Date
ES2061496T3 true ES2061496T3 (en) 1994-12-16

Family

ID=25348060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87304642T Expired - Lifetime ES2061496T3 (en) 1986-05-27 1987-05-26 INTRALESIONAL TREATMENT OF BASAL CELL CARCINOMA WITH RECOMBINANT ALPHA-HUMAN INTERFERON.

Country Status (13)

Country Link
EP (1) EP0248583B1 (en)
JP (1) JPS62289526A (en)
KR (1) KR870010871A (en)
AT (1) ATE100717T1 (en)
AU (1) AU601741B2 (en)
CA (1) CA1295243C (en)
DE (1) DE3788899T2 (en)
DK (1) DK264787A (en)
ES (1) ES2061496T3 (en)
IE (1) IE62318B1 (en)
IL (1) IL82654A0 (en)
PH (1) PH26198A (en)
ZA (1) ZA873743B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
EP0278715A3 (en) * 1987-02-09 1989-03-08 Schering Corporation Use of human gamma interferon for treatment of basal cell carcinoma
US5256410A (en) * 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
MY107071A (en) * 1988-12-01 1995-09-30 Schering Corp Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
PT99837A (en) * 1990-12-21 1992-12-31 Schering Corp PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING ALPHA INTERFERENCE AND METHOD FOR ADMINISTRATION OF ALPHA INTERFERENCE BY ORAL INHALATION TO TREAT ASTHMA AND PROLIFERATIVE PULMONARY DISEASES NOT MALIGNANT
EP3600379B1 (en) 2017-03-31 2022-12-21 Accanis Biotech F&E GmbH & Co KG Prevention and treatment of non-melanoma skin cancer (nmsc)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3278234D1 (en) * 1981-10-13 1988-04-21 Exovir Inc Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
US5098703A (en) * 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
AU1152983A (en) * 1982-01-15 1983-07-28 Cetus Corporation Interferon alpha 74
AU1153083A (en) * 1982-01-15 1983-07-28 Cetus Corporation Interferon-alpha 54
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex

Also Published As

Publication number Publication date
EP0248583A2 (en) 1987-12-09
ZA873743B (en) 1987-11-25
JPS62289526A (en) 1987-12-16
ATE100717T1 (en) 1994-02-15
AU601741B2 (en) 1990-09-20
CA1295243C (en) 1992-02-04
DE3788899D1 (en) 1994-03-10
PH26198A (en) 1992-03-18
IL82654A0 (en) 1987-11-30
EP0248583B1 (en) 1994-01-26
DK264787A (en) 1987-11-28
DK264787D0 (en) 1987-05-25
AU7336687A (en) 1987-12-03
EP0248583A3 (en) 1989-10-18
DE3788899T2 (en) 1994-05-05
IE62318B1 (en) 1995-01-25
KR870010871A (en) 1987-12-18
IE871358L (en) 1987-11-27

Similar Documents

Publication Publication Date Title
DE3684732D1 (en) ADOPTIVE IMMUNOTHERAPY AS A TREATMENT MODALITY IN PEOPLE.
BG60253B1 (en) HUMAN TISSUE PLASMINOGENIC ACTIVATOR
DE3677897D1 (en) HUMAN COMPLEMENT FACTORS AND THEIR THERAPEUTIC USE.
DE3583849D1 (en) USE OF INTERFERON GAMMA (IFN-GAMMA) CONTAINERS FOR THE SYSTEMIC TREATMENT OF VARIOUS DISEASES OF HUMAN IN LOW DOSAGE.
SE8802569D0 (en) IMPROVEMENTS IN OR RELATION TO SOMATOSTATINS
UA29466C2 (en) PHARMACEUTICAL COMPOSITION WITH ANTI-TUMOR ACTIVITY
ATE74272T1 (en) PHARMACEUTICAL SUBSTANCE FOR THE TREATMENT OF MYELOGOUS LEUKEMIA.
ATE240116T1 (en) USE OF HUMAN BETA INTERFERON FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC MYELOIDLEUKEMIA
ES2115582T3 (en) PREPARATION AND APPLICATIONS OF INTERFERON-GAMMA.
ATE67783T1 (en) HOMOGENEOUS RECOMBINANT IMMUNE INTERFERON FRAGMENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
KR910018038A (en) Use of a human interleukin 2-active containing polypeptide for the manufacture of a pharmaceutical composition for the treatment of primary pleural cancer
DE3788899D1 (en) Intralesional treatment of basal cell carcinoma using recombinant human alpha interferons.
ES2039236T3 (en) METHOD FOR PREPARING A THERAPEUTIC COMPOSITION OF INTERLENQUINE-2 AND / OR INTERFERON-BETA AND TUMOR NECROSIS FACTOR.
DE68908119D1 (en) MEDICINAL PRODUCTS FOR INTRALESION TREATMENT OF DOMESTIC CELL CARCINOMAS WITH RECOMBINANT HUMAN ALPHA INTERFERON.
Deichmann et al. Non‐human immunodeficiency virus Kaposi's sarcoma can be effectively treated with low‐dose interferon‐α despite the persistence of herpesvirus‐8
OA08768A (en) Treatment of AIDS virus with recombinant human alpha interferon.
ES2039276T3 (en) USE OF A COMBINATION OF INTERFERON GAMMA AND INTERFERON ALPHA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CERTAIN LEUKEMIA.
KR927003083A (en) Antitumor Compositions Based on Polypeptides Having Human Interleukin 2 Activity
ATE130194T1 (en) SUBCUTANEOUS ADMINISTRATION OF HUMAN CHORIONIC GONADOTROPINE.
KR900700156A (en) Improved Radiation Therapy
Richtsmeier The interferons
IT1224673B (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ANALOG OF SOMATOSTATIN ESUO USE IN THE TREATMENT OF BREAST CANCER
KR920014480A (en) Use of a polypeptide having activity of human interleukin 2 to prepare a pharmaceutical composition for treating pneumothorax
FR2791894B1 (en) USE OF INTERFERON BETA IN THE TREATMENT OF EWING'S TUMOR
KR900012628A (en) Treatment for ovarian cancer for intraperitoneal administration containing an effective amount of gamma interferon

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 248583

Country of ref document: ES